Josef Ozer

3.8k citations

27 papers · 2.5k indexed · 2 hit papers · h-index 18

Molecular Biology top 10%
Pharmacology top 0.5%
Nephrology top 2%
Epidemiology top 10%
Plant Science top 10%

Co-authors: Wendy Bailey Marcia H. Ratner Martin Shaw Shelli Schomaker Paul M. Lieberman Paul A. Moore Arthur H. Bolden Nagaraja Muniappa
Topics: RNA Research and Splicing (6 papers)Genomics and Chromatin Dynamics (6 papers)Drug-Induced Hepatotoxicity and Protection (4 papers)
Cited by: Nephrology Pharmacology Hepatology
Journals: Journal of Biological Chemistry Journal of Clinical Investigation Genes & Development
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Josef Ozer

27 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The current state of serum biomarkers of hepatotoxicity

2007 999 citations Josef Ozer, Marcia H. Ratner et al. Toxicology profile →
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies

2010 520 citations Vishal S. Vaidya, Josef Ozer et al. Nature Biotechnology profile →

Peers

Countries citing papers authored by Josef Ozer

Since Specialization

Citations

This map shows the geographic impact of Josef Ozer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josef Ozer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josef Ozer more than expected).

Fields of papers citing papers by Josef Ozer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josef Ozer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josef Ozer. The network helps show where Josef Ozer may publish in the future.

Co-authorship network of co-authors of Josef Ozer

This figure shows the co-authorship network connecting the top 25 collaborators of Josef Ozer. A scholar is included among the top collaborators of Josef Ozer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josef Ozer. Josef Ozer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Younger age at onset of sporadic Parkinson’s disease among subjects occupationally exposed to metals and pesticides 2014 ·Interdisciplinary Toxicology ·Marcia H. Ratner,David H. Farb,Josef Ozer,Robert G. Feldman,Raymon Durso	30
2	Quantitative Analysis of Target Coverage and Germinal Center Response by a CXCL13 Neutralizing Antibody in a T-Dependent Mouse Immunization Model 2013 ·Pharmaceutical Research ·Joanne Brodfuehrer,Andrew L. Rankin,Jason Edmonds,Sean Keegan,Tatyana Andreyeva,(unknown),Josef Ozer,(unknown),Laird Bloom,(unknown),(unknown),Julie Lee,Timothy P. LaBranche,Jameel Syed,Wenyan Miao,(unknown)	17
3	A Systematic Approach to Preclinical and Clinical Safety Biomarker Qualification Incorporating Bradford Hill's Principles of Causality Association 2010 ·Clinical Pharmacology & Therapeutics ·(unknown),Josef Ozer,Anne Lanevschi,Ina Schuppe‐Koistinen,(unknown),John Pears,Jacky Vonderscher,Frank D. Sistare,Frank Dieterle	7
4	Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studiesbreakdown → 2010 ·Nature Biotechnology ·Vishal S. Vaidya,Josef Ozer,Frank Dieterle,(unknown),Victoria Ramírez,Sean P. Troth,Nagaraja Muniappa,Douglas T. Thudium,David Gerhold,Daniel Holder,Norma A. Bobadilla,Estelle Marrer,Elias Perentes,André Cordier,Jacky Vonderscher,Gerald Maurer,Peter L. Goering,Frank D. Sistare,Joseph V. Bonventre	520
5	Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury 2010 ·Nature Biotechnology ·Yan Yu,Hong Jin,Daniel Holder,Josef Ozer,Stephanie Villarreal,Paul J. Shughrue,Shi Shu,David J. Figueroa,Holly Clouse,(unknown),Nagaraja Muniappa,Sean P. Troth,Wendy Bailey,John E. Seng,Amy G. Aslamkhan,Douglas T. Thudium,Frank D. Sistare,David Gerhold	147
6	Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization 2009 ·Journal of Chromatography B ·Joe Palandra,(unknown),Josef Ozer,Yanhua Zhang,Timothy G. Heath	39
7	A guidance for renal biomarker lead optimization and use in translational pharmacodynamics 2009 ·Drug Discovery Today ·Josef Ozer	8
8	Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury 2009 ·Regulatory Toxicology and Pharmacology ·Josef Ozer,(unknown),J. Gerry Kenna,Joe Palandra,Yiqun Zhang,Anne Lanevschi,Nandan Koppiker,Bernard Souberbielle,Shashi K. Ramaiah	58
9	The current state of serum biomarkers of hepatotoxicitybreakdown → 2007 ·Toxicology ·Josef Ozer,Marcia H. Ratner,Martin Shaw,Wendy Bailey,Shelli Schomaker	999
10	Transcription Factor IIA τ Is Associated with Undifferentiated Cells and Its Gene Expression Is Repressed in Primary Neurons at the Chromatin Level In Vivo 2006 ·Stem Cells and Development ·(unknown),(unknown),Shamol Saha,Michael Buratovich,(unknown),Heath D. Schmidt,(unknown),(unknown),Gleb S. Ivanov,Stefan Przyborski,Josef Ozer	3
11	Sp and GATA factors are critical for Apolipoprotein AI downstream enhancer activity in human HepG2 cells 2003 ·Gene ·Gleb S. Ivanov,(unknown),(unknown),(unknown),(unknown),(unknown),Geoffrey S. Ginsburg,Josef Ozer	4
12	A Testis-specific Transcription Factor IIA (TFIIAτ) Stimulates TATA-binding Protein-DNA Binding and Transcription Activation 2000 ·Journal of Biological Chemistry ·Josef Ozer,Paul A. Moore,Paul M. Lieberman	49
13	A Human TATA Binding Protein-Related Protein with Altered DNA Binding Specificity Inhibits Transcription from Multiple Promoters and Activators 1999 ·Molecular and Cellular Biology ·Paul A. Moore,Josef Ozer,(unknown),Gwénaël Jan,Dennis Zerby,Susan Campbell,Paul M. Lieberman	82
14	Transcription Factor IIA Derepresses TATA-binding Protein (TBP)-associated Factor Inhibition of TBP-DNA Binding 1998 ·Journal of Biological Chemistry ·Josef Ozer,Katherine Mitsouras,Dennis Zerby,Michael Carey,Paul M. Lieberman	50
15	An Imperfect Correlation between DNA Replication Activity of Epstein–Barr Virus Nuclear Antigen 1 (EBNA1) and Binding to the Nuclear Import Receptor, Rch1/importin α 1997 ·Virology ·Arianna L. Kim,Maureen Maher,(unknown),Josef Ozer,Dennis Zerby,John L. Yates,Paul M. Lieberman	36
16	Transcription Factor IIA Mutations Show Activator-specific Defects and Reveal a IIA Function Distinct from Stimulation of TBP-DNA Binding 1996 ·Journal of Biological Chemistry ·Josef Ozer,Arthur H. Bolden,Paul M. Lieberman	46
17	Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4. 1995 ·Journal of Clinical Investigation ·Geoffrey S. Ginsburg,Josef Ozer,S K Karathanasis	54
18	The human myeloid cell nuclear differentiation antigen gene is one of at least two related interferon-inducible genes located on chromosome 1q that are expressed specifically in hematopoietic cells 1994 ·Blood ·(unknown),(unknown),Josef Ozer,Linda Sealy,(unknown),(unknown),(unknown),(unknown),R. S. Athwal,EN Dessypris	45
19	Isolation of the CCAAT transcription factor subunit EFIA cDNA and a potentially functional EFIA processed pseudogene from Bos taurus: insights into the evolution of the EFIA/dbpB/YB-1 gene family 1993 ·Gene ·Josef Ozer,Roger Chalkley,Linda Sealy	14
20	Characterization of rat pseudogenes for enhancer factor I subunit A: ripping provides clues to the evolution of the EFIAdbpB/YB-1 multigene family 1993 ·Gene ·Josef Ozer,Roger Chalkley,Linda Sealy	7

About Josef Ozer

Josef Ozer is a scholar working on Pharmacology, Nephrology and Toxicology, having authored 27 papers that have together received 2.5k indexed citations. Recurring topics across this work include RNA Research and Splicing (6 papers), Genomics and Chromatin Dynamics (6 papers) and Drug-Induced Hepatotoxicity and Protection (4 papers). The work is most often cited by research in Nephrology (362 citations), Pharmacology (442 citations) and Hepatology (143 citations). Josef Ozer has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Wendy Bailey, Marcia H. Ratner, Martin Shaw, Shelli Schomaker, Paul M. Lieberman, Paul A. Moore, Arthur H. Bolden, Nagaraja Muniappa, Douglas T. Thudium and Daniel Holder. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact